Significance of glomerular fibrinogen deposition in children with Henoch-Schönlein purpura nephritis

Henoch-Schönlein purpura nephritis.

Henoch-Schönlein purpura (HSP) is a systemic vasculitic disorder first reported by Heberden in 1806. The association of purpura and joint pain was described by Schönlein in 1837, who termed it “peliosis rheumatica.” Henoch added a description of four children with skin lesions associated with colicky abdominal pain, gastrointestinal hemorrhage, and joint pain in 1874, and in 1899 pointed out th...

Azathioprine treatment in two children with Henoch–Schönlein purpura nephritis

Henoch-Schönlein purpura nephritis in children: incidence, pathogenesis and management.

BACKGROUND Henoch-Schönlein purpura (HSP) is one of the most common vasculitides in children. It is manifested by skin purpura, arthritis, abdominal pain, renal involvement, etc. Typically, HSP is considered to be self-limiting, although renal involvement (HSP purpura nephritis, HSPN) is the principal cause of morbidity from this disease. For this reason, it is important to clarify the mechanis...

Henoch-Schönlein purpura in children.

Henoch-Schönlein purpura is the most common systemic vasculitis of childhood. In the majority of children, the outcome of Henoch-Schönlein purpura is excellent with spontaneous resolution of symptoms and signs. However, a small subset of patients will develop long-term sequelae in the form of chronic kidney disease. While the clinical presentation and diagnosis of Henoch-Schönlein purpura is st...

Chapter 11: Henoch-Schönlein purpura nephritis

11.1: Treatment of HSP nephritis in children 11.1.1: We suggest that children with HSP nephritis and persistent proteinuria, 40.5-1 g/d per 1.73 m, are treated with ACE-I or ARBs. (2D) 11.1.2: We suggest that children with persistent proteinuria, 41 g/d per 1.73 m, after a trial of ACE-I or ARBs, and GFR 450 ml/min per 1.73 m, be treated the same as for IgAN with a 6-month course of corticoster...